Benzinga | Dec 8, 2021 09:06AM EST

Edwards Lifesciences Reaffirms FY21 Guidance

* Reaffirming October 2021 financial guidance

* Projecting 2022 global sales of $5.5 - $6.0 billion; underlying growth in the low double-digits

* Projecting 2022 TAVR sales of $3.7 - $4.0 billion; underlying growth 12-15%

* Projecting 2022 TMTT sales of $140 - $170 million

* Estimating 2022 adjusted earnings per share $2.50 - $2.65

* Focused long-term growth investments with 2022 R&D planned at 17-18% of sales

* Meaningful progress on 7 pivotal trials across TAVR and TMTT

* Global market opportunity across 4 product groups projected to double to nearly $20 billion by 2028